<PAGE> 1
Securities and Exchange Commission
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report December 16, 1999
-------------------
(Date of earliest event reported)
DATATRAK INTERNATIONAL, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Ohio (000-20699) 34-1685364
- ------------------------------- --------------------- --------------------
(State or other jurisdiction of (Commission File No.) (I.R.S. Employer
incorporation) Identification No.)
20600 Chagrin Boulevard, Cleveland, Ohio 44122
- ---------------------------------------------------- ---------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (216) 921-6505
--------------
Page 1 of 5 Pages
Exhibit Index Appears on Page 3
<PAGE> 2
ITEM 5. OTHER EVENTS
- --------------------
On December 16, 1999, DataTRAK International, Inc. announced that
Jerome H. Kaiser, Ph.D., was named to the Company's Board of Directors. Dr.
Kaiser was elected at a meeting of the Board on December 9, 1999. Dr. Jerry
Kaiser (age 43) currently serves as the Director of Systems at Rothschild Inc.
in New York. Most recently, Dr. Kaiser was Director of Product Management,
Corporate Clinical and Regulatory Systems for Pfizer in its New York City
headquarters. He has also held the position of Director of Information
Management, Global Development for Hoffman-LaRoche Pharmaceuticals, Inc. in
Nutley, New Jersey. Dr. Kaiser is a business technology executive with
experience pertaining to large-scale, high-value change projects involving
organizational and process re-engineering within the pharmaceutical industry.
Dr. Kaiser holds a Ph.D. in Physics from the University of East Anglia, Norwich,
England.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DataTRAK INTERNATIONAL, INC.
By: /s/ Terry C. Black
--------------------------------
Terry C. Black
Vice President of Finance, Chief Financial
Officer, Treasurer and Assistant Secretary
Date: December 17, 1999
Page 2 of 5 Pages
<PAGE> 3
EXHIBIT INDEX
-------------
EXHIBIT NO. DESCRIPTION PAGE
----------- ----------- ----
99.1 Press Release Issued by the Company
on December 16, 1999. 4
Page 3 of 5 Pages
<PAGE> 1
EXHIBIT 99.1
FOR IMMEDIATE RELEASE:
DATATRAK INTERNATIONAL NAMES DIRECTOR
CLEVELAND, December 16, 1999--DataTRAK International, Inc. (Nasdaq:
DATA) announced today that Jerome H. Kaiser, Ph.D., has been named to the
Company's Board of Directors. Dr. Kaiser was elected at a meeting of the Board
on December 9, 1999.
Dr. Jerry Kaiser (age 43) currently serves as the Director of Systems
at Rothschild Inc. in New York. Most recently, Dr. Kaiser was Director of
Product Management, Corporate Clinical and Regulatory Systems for Pfizer in its
New York City headquarters. He has also held the position of Director of
Information Management, Global Development for Hoffman-LaRoche Pharmaceuticals,
Inc. in Nutley, New Jersey. Dr. Kaiser is a business technology executive with
experience pertaining to large-scale, high-value change projects involving
organizational and process re-engineering within the pharmaceutical industry.
Dr. Kaiser holds a Ph.D. in Physics from the University of East Anglia, Norwich,
England.
Dr. Kaiser stated, "The opportunity to work with DataTRAK
International, Inc. as the leading and most experienced Application Service
Provider in the electronic data capture marketplace is both exciting and
challenging. The pharmaceutical industry can realize significant competitive
advantages from transitioning its clinical workflow from paper to
automation-based processes and publicly presented metrics have demonstrated this
with DataTRAK EDC (TM). Management performed a very logical and detailed
analysis in the selection of Citrix Metaframe (TM) as its platform for the
centralized distribution of DataTRAK EDC (TM) giving careful consideration to
worldwide scalability and performance issues. The growing adoption of Citrix is
a testimony to the accuracy of that evaluation. Such a platform offers superior
performance metrics over traditional approaches to Internet solutions such as
HTML."
"I am pleased to welcome Dr. Kaiser to our Board of Directors. His
extensive experience within the pharmaceutical industry combined with his focus
on the use of technology to improve workflow will be extremely beneficial as
DataTRAK continues to be an innovator in this growing market," stated Dr.
Jeffrey A. Green, President and Chief Executive Officer of DataTRAK
International, Inc.
DataTRAK International, Inc. is a worldwide Application Service
Provider (ASP) for the EDC industry. DataTRAK provides a suite of EDC software
products known as DataTRAK EDC (TM) and related hosting, educational, and
training services to the pharmaceutical, biotechnology, and medical device
industries. DataTRAK EDC (TM) was developed in order to deliver clinical
research data from investigative sites to sponsors faster and more efficiently
than conventional manual methods. DataTRAK EDC (TM) can be deployed worldwide in
either a distributed platform using laptop computers or in a centralized server
"thin client" environment using the Internet. DataTRAK EDC (TM) software and its
earlier versions have successfully supported more than 37 clinical studies at
more than 800 clinical sites in 26 countries encompassing 20,000 patients.
DataTRAK International, Inc. has offices and hosting facilities located in
Cleveland, Ohio and Bonn, Germany. Visit the DataTRAK International, Inc. web
site at www.datatraknet.com or www.datatraknet.de.
Except for historical information contained in this press release, the
statements made in this release are forward-looking statements. Factors that may
cause actual results to differ materially from those in the forward-looking
statements include the ability of DataTRAK to
Page 4 of 5
<PAGE> 2
absorb corporate overhead and other fixed costs in order to successfully market
the DataTRAK EDC (TM) software; the development and fluctuations in the market
for EDC technology; continued unreliability of the Internet infrastructure; the
degree of DataTRAK's success in obtaining new contracts; the timing of payments
from sponsors and the timing of sponsor decisions to conduct new clinical trials
or cancel or delay ongoing trials; dependence on key personnel; governmental
regulation; the early stage of the DataTRAK business and operations; and general
economic conditions. In addition, DataTRAK's success depends on the outcome of
various strategic initiatives it has undertaken, all of which are based on
assumptions made by DataTRAK concerning trends in the clinical research market
and the health care industry.
/CONTACT: Jeffrey A. Green, Pharm.D., FCP, President and Chief
Executive Officer, ext. 112, or Terry C. Black, Chief Financial Officer, ext.
110, both of DataTRAK International, Inc., (216) 921-6505./
Page 5 of 5
